69,659 Shares in Catalent, Inc. (NYSE:CTLT) Acquired by HGC Investment Management Inc.

HGC Investment Management Inc. purchased a new position in shares of Catalent, Inc. (NYSE:CTLT) in the third quarter, HoldingsChannel reports. The fund purchased 69,659 shares of the company’s stock, valued at approximately $4,219,000. Catalent comprises 1.8% of HGC Investment Management Inc.’s portfolio, making the stock its 18th biggest holding.

A number of other large investors also recently bought and sold shares of the business. Brooklyn Investment Group purchased a new stake in Catalent in the 3rd quarter valued at approximately $31,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Catalent during the 2nd quarter valued at about $42,000. Sentry Investment Management LLC bought a new stake in shares of Catalent during the third quarter worth approximately $53,000. Longfellow Investment Management Co. LLC boosted its holdings in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares during the period.

Catalent Trading Up 0.6 %

CTLT stock opened at $61.45 on Tuesday. The business has a fifty day moving average price of $59.93 and a 200-day moving average price of $58.55. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $61.50. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business’s revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.10) EPS. On average, equities research analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current year.

Insider Activity

In other news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 5,114 shares of company stock worth $305,931. Company insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CTLT. William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. StockNews.com upgraded Catalent from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Robert W. Baird restated a “neutral” rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, According to MarketBeat, Catalent presently has an average rating of “Hold” and an average price target of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.